223 related articles for article (PubMed ID: 12358251)
1. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
4. Effect of tegaserod on gut transit in male and female subjects.
Degen L; Petrig C; Studer D; Schroller S; Beglinger C
Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
[TBL] [Abstract][Full Text] [Related]
5. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
7. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
8. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.
Rodriguez-Stanley S; Zubaidi S; Proskin HM; Kralstein JR; Shetzline MA; Miner PB
Clin Gastroenterol Hepatol; 2006 Apr; 4(4):442-50. PubMed ID: 16616348
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
10. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
Tegaserod Clinical Research Group
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
[TBL] [Abstract][Full Text] [Related]
11. Review article: the safety profile of tegaserod.
Schoenfeld P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A
Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272
[TBL] [Abstract][Full Text] [Related]
13. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
[TBL] [Abstract][Full Text] [Related]
14. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
15. Review article: tegaserod for chronic constipation.
Johanson JF
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():20-4. PubMed ID: 15521851
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.
Müller-Lissner S; Kamm MA; Musoglu A; Earnest DL; Dunger-Baldauf C; Shetzline MA
Am J Gastroenterol; 2006 Nov; 101(11):2558-69; quiz 2671. PubMed ID: 17090282
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tegaserod in chronic constipation in men.
Fried M; Johanson JF; Gwee KA; Wagner A; Pecher E; Rueegg P
Am J Gastroenterol; 2007 Feb; 102(2):362-70. PubMed ID: 17156137
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
20. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH.
Tutuian R; Mainie I; Allan R; Hargreaves K; Agrawal A; Freeman J; Gale J; Castell DO
Aliment Pharmacol Ther; 2006 Jul; 24(1):155-62. PubMed ID: 16803614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
